BIO-TECHNE Corp

Bio-Techne Corporation

Overview

• Bio-Techne Corporation and its subsidiaries develop, manufacture, and sell life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
• Global headquarters: Minneapolis, Minnesota. Founded in 1976 as Research and Diagnostic Systems, Inc.; became public in 1985 via merger with Techne Corporation.
• Traded on NASDAQ under the symbol TECH.
• Business strategy pillars: Grow & Leverage the Core; Capitalize on High Potential Markets; Market Expansion Through Innovation & Acquisition; Deliver Best-in-Class Customer Experience; Develop People Through a Transformative Culture (EPIC: Empowerment, Passion, Innovation, Collaboration).

Operating structure

• Two operating segments:
  • Protein Sciences (approximately 72% of net sales in fiscal 2026)
    • Reagent Solutions: specialized proteins (cytokines, growth factors), antibodies, small molecules, tissue culture sera, cell selection technologies; serves researchers and cell/gene therapy developers; includes cGMP protein production capabilities.
    • Analytical Solutions: manual and automated protein analysis instruments and immunoassays, including automated western blotting and multiplex immunoassays. Key brands include R&D Systems, Tocris Biosciences, and Novus Biologicals.
  • Diagnostics and Spatial Biology (approximately 28% of net revenues in fiscal 2026)
    • Spatial Biology: Advanced Cell Diagnostics (ACD) brand with in-situ hybridization (ISH) assays for transcriptome, DNA copy, and structural variation analysis in intact cells. The Lunaphore acquisition (fiscal 2024) added automated spatial biology platforms, including the COMET instrument for RNAscope and hyperplex protein/RNA detection.
    • Bio-Techne Diagnostic: regulated diagnostic reagents, calibrators, controls, and instrument/process control products for hematology, chemistry, blood gases, and coagulation, primarily sold OEM to instrument manufacturers, with many FDA-cleared products.
    • Asuragen: branded genetic testing workflows sold to labs for laboratory-developed tests (LDTs) or kit-based diagnostics.
• No single customer accounted for 10% or more of net sales in either segment in fiscal 2026, 2025, or 2024.

Products and portfolio

• Offers hundreds of thousands of products across multiple manufacturing locations, providing a broad toolset for life sciences research, diagnostics, and bioprocessing.
• Introduced over 1,900 new products in fiscal 2026.
• Product applications span disease areas including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure.
• Some immunoassays have FDA marketing clearance for in vitro diagnostic use.

Global footprint and customers

• Customer base includes academic researchers, pharmaceutical and biotech companies, contract research organizations, diagnostic and companion diagnostic developers, and therapeutic developers (including cell and gene therapies).
• Primary direct sales to customers in North America, Europe, and China; distribution through Thermo Fisher Scientific and additional third-party distributors in China, Japan, Eastern Europe, and other regions.
• Approximately 48% of fiscal 2026 revenue was generated outside the U.S.

Employees and culture

• Approximately 3,000 full-time and part-time employees as of June 30, 2026:
  • About 2,200 in the U.S.; about 800 outside the U.S.
  • U.S. workforce is non-union; certain foreign locations operate under government-mandated collective bargaining agreements or works councils.
• EPIC values: Empowerment, Passion, Innovation, Collaboration. Eleven Employee Resource Groups (ERGs) globally as of June 30, 2026.
• Workforce composition (as of June 30, 2026): 48% of total workforce female; 44% of managerial population female; 22% of total workforce identified as nonwhite; 20% of managerial population identified as nonwhite.

Research, development, and innovation

• Ongoing R&D and product development to address changing needs in life sciences markets.
• Global learning and development programs with emphasis on internal growth, succession planning, and leadership development.
• IP strategy includes a substantial patent portfolio and licensing arrangements with third parties.

Intellectual property

• Approximately 487 granted patents and about 230 pending patent applications as of June 30, 2026.
• IP protection through patents, trade secrets, and trademarks, supplemented by licenses from third parties.
• Risks include potential infringement by others and reliance on protection of trade secrets.

Manufacturing and supply chain

• Manufacturing sites in Canada, Switzerland, China, the U.K., and multiple owned facilities:
  • Minneapolis complex: ~800,000 sq ft (production, R&D, shipping/warehousing); ~710,000 sq ft used for operations.
  • Saint Paul, MN: ~61,000 sq ft manufacturing.
  • Wallingford, CT: ~53,000 sq ft.
  • Abingdon, England: ~16,000 sq ft.
  • Toronto, Canada: ~9,000 sq ft.
• Additional leased facilities across the U.S., Europe, and Asia, including Lunaphore in Tolochenaz, Switzerland.
• Shipping: majority of products shipped within one day of order; instruments and related cartridges typically shipped within 1–2 weeks.
• Supply chain: diverse supplier base with some sole or limited-source components; exposure to raw material costs, lead times, and logistics. Safety stock and multiple sourcing are used to mitigate disruption risks.

Financial and liquidity context

• Pending merger: Agreement with Merck KGaA, Darmstadt, Germany announced June 25, 2026.
  • Consideration: $73.00 in cash per share (excluding certain shares).
  • Expected close: late 2026 or early 2027, subject to customary closing conditions and regulatory approvals; includes potential termination fee arrangements and restrictions during the pendency.
• M&A and investments:
  • 19.9% investment in Wilson Wolf Corporation (2023) with plans to acquire the remaining stake by the end of calendar year 2027.
  • Lunaphore acquisition completed at the start of fiscal 2024.
  • Collaboration through ScaleReady LLC with Wilson Wolf and another partner.
• Debt and liquidity: revolving credit facility of up to $1.0 billion (increaseable to $1.4 billion); $200 million drawn as of August 17, 2026.
• Backlog and order dynamics: shipments generally fulfill orders promptly.
• Dividends: historically declared quarterly dividends; the Merger imposes certain dividend-related restrictions.

Regulatory and risk context

• Products include medical devices and regulated diagnostics subject to FDA and international regulatory regimes, including the EU IVDR.
• Operations are subject to U.S. and international healthcare laws (privacy, anti-kickback, False Claims Act, HIPAA, Open Payments) and export/import controls, with associated compliance obligations and potential penalties.
• Cybersecurity and data privacy oversight is at the board level via the Audit Committee, with annual risk management, incident response planning, employee training, and cyber insurance in place.

Business characteristics

• The company focuses on growth through acquisitions, geographic expansion (including China, India, and other developing markets), and maintaining a strong balance sheet to support investments.
• The Protein Sciences segment experiences seasonality tied to academic schedules; Diagnostics and Spatial Biology demand is more variable and linked to customer procurement cycles.

In short, Bio-Techne is a global developer, manufacturer, and marketer of life science tools and diagnostics products, organized into Protein Sciences and Diagnostics & Spatial Biology, with a broad product catalog, ongoing investments in acquisitions and technology, a substantial IP portfolio, and a pending cash merger with Merck KGaA.